Literature DB >> 24188011

Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update.

Francesco Peri1, Valentina Calabrese.   

Abstract

Toll-like receptor 4 (TLR4), together with MD-2, binds bacterial endotoxins (E) with high affinity, triggering formation of the activated homodimer (E.MD-2.TLR4)2. Activated TLR4 induces intracellular signaling leading to activation of transcription factors that result in cytokine and chemokine production and initiation of inflammatory and immune responses. TLR4 also responds to endogenous ligands called danger associated molecular patterns (DAMPs). Increased sensitivity to infection and a variety of immune pathologies have been associated with either too little or too much TLR4 activation. We review here the molecular mechanisms of TLR4 activation (agonism) or inhibition (antagonism) by small organic molecules of both natural and synthetic origin. The role of co-receptors MD-2 and CD14 in the TLR4 modulation process is also discussed. Recent achievements in the field of chemical TLR4 modulation are reviewed, with special focus on nonclassical TLR4 ligands with a chemical structure different from that of lipid A.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24188011      PMCID: PMC4040398          DOI: 10.1021/jm401006s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  70 in total

1.  A synthetic lipid A mimetic modulates human TLR4 activity.

Authors:  Matteo Piazza; Valentina Calabrese; Gaetana Damore; Roberto Cighetti; Theresa Gioannini; Jerrold Weiss; Francesco Peri
Journal:  ChemMedChem       Date:  2011-12-02       Impact factor: 3.466

2.  Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa.

Authors:  Umeharu Ohto; Koichi Fukase; Kensuke Miyake; Yoshinori Satow
Journal:  Science       Date:  2007-06-15       Impact factor: 47.728

3.  Suppression of MyD88- and TRIF-dependent signaling pathways of Toll-like receptor by (-)-epigallocatechin-3-gallate, a polyphenol component of green tea.

Authors:  Hyung S Youn; Joo Y Lee; Shin I Saitoh; Kensuke Miyake; Keon W Kang; Yong J Choi; Daniel H Hwang
Journal:  Biochem Pharmacol       Date:  2006-08-04       Impact factor: 5.858

4.  Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2.

Authors:  So Young Kim; Jung Eun Koo; Yun Jee Seo; Nisha Tyagi; Eunshil Jeong; Jaeyoung Choi; Kyung-Min Lim; Zee-Yong Park; Joo Young Lee
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

5.  Synthesis of serine-based glycolipids as potential TLR4 activators.

Authors:  Li-De Huang; Hong-Jyune Lin; Po-Hsiung Huang; Wei-Chen Hsiao; L Vijaya Raghava Reddy; Shu-Ling Fu; Chun-Cheng Lin
Journal:  Org Biomol Chem       Date:  2011-02-21       Impact factor: 3.876

6.  Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages.

Authors:  Ji-Yeon Kim; Seung Jae Park; Kyung-Jin Yun; Young-Wuk Cho; Hee-Juhn Park; Kyung-Tae Lee
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

7.  Paclitaxel ameliorates lipopolysaccharide-induced kidney injury by binding myeloid differentiation protein-2 to block Toll-like receptor 4-mediated nuclear factor-κB activation and cytokine production.

Authors:  Dongshan Zhang; Yijian Li; Yu Liu; Xudong Xiang; Zheng Dong
Journal:  J Pharmacol Exp Ther       Date:  2013-01-14       Impact factor: 4.030

8.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

9.  TBK1-targeted suppression of TRIF-dependent signaling pathway of Toll-like receptors by 6-shogaol, an active component of ginger.

Authors:  Se-Jeong Park; Mi-Young Lee; Bu-Soon Son; Hyung-Sun Youn
Journal:  Biosci Biotechnol Biochem       Date:  2009-07-07       Impact factor: 2.043

Review 10.  Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway.

Authors:  Kurt Lucas; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-02-26       Impact factor: 5.590

View more
  45 in total

Review 1.  Understanding the Role of Innate Immunity in the Response to Intracortical Microelectrodes.

Authors:  John K Hermann; Jeffrey R Capadona
Journal:  Crit Rev Biomed Eng       Date:  2018

Review 2.  Lipid A structural modifications in extreme conditions and identification of unique modifying enzymes to define the Toll-like receptor 4 structure-activity relationship.

Authors:  Alison J Scott; Benjamin L Oyler; David R Goodlett; Robert K Ernst
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-01-17       Impact factor: 4.698

3.  Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Lijing Su; Murali M R P Surakattula; Michael Berger; Hua Huang; Elliot K Beutler; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2016-04-25       Impact factor: 7.446

4.  Dexmedetomidine reduces ventilator-induced lung injury (VILI) by inhibiting Toll-like receptor 4 (TLR4)/nuclear factor (NF)-κB signaling pathway.

Authors:  Hongli Chen; Xiaotong Sun; Xiaomei Yang; Yonghao Hou; Xiaoqian Yu; Yang Wang; Jianbo Wu; Dejie Liu; Huanliang Wang; Jingui Yu; Wenbo Yi
Journal:  Bosn J Basic Med Sci       Date:  2018-05-20       Impact factor: 3.363

5.  TLR4 in skin cancer: From molecular mechanisms to clinical interventions.

Authors:  Sally E Dickinson; Georg T Wondrak
Journal:  Mol Carcinog       Date:  2019-04-24       Impact factor: 4.784

6.  Anticancer Mechanisms in Two Murine Bone Marrow-Derived Dendritic Cell Subsets Activated with TLR4 Agonists.

Authors:  Alexander Bagaev; Aleksey Pichugin; Edward L Nelson; Michael G Agadjanyan; Anahit Ghochikyan; Ravshan I Ataullakhanov
Journal:  J Immunol       Date:  2018-03-02       Impact factor: 5.422

Review 7.  Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy.

Authors:  Giacomo Garibotto; Annalisa Carta; Daniela Picciotto; Francesca Viazzi; Daniela Verzola
Journal:  J Nephrol       Date:  2017-09-20       Impact factor: 3.902

8.  Inhibition of the cluster of differentiation 14 innate immunity pathway with IAXO-101 improves chronic microelectrode performance.

Authors:  John K Hermann; Madhumitha Ravikumar; Andrew J Shoffstall; Evon S Ereifej; Kyle M Kovach; Jeremy Chang; Arielle Soffer; Chun Wong; Vishnupriya Srivastava; Patrick Smith; Grace Protasiewicz; Jingle Jiang; Stephen M Selkirk; Robert H Miller; Steven Sidik; Nicholas P Ziats; Dawn M Taylor; Jeffrey R Capadona
Journal:  J Neural Eng       Date:  2018-04       Impact factor: 5.379

9.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

Review 10.  Big opportunities for small molecules in immuno-oncology.

Authors:  Jerry L Adams; James Smothers; Roopa Srinivasan; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2015-07-31       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.